Abstract
Nephrogenic systemic fibrosis (NSF) is a systemic fibrosing disorder that mimics systemic sclerosis (scle-roderma) and is strongly associated with exposure to gadolinium in the setting of renal insufficiency. In addition to the skin, fibrotic changes can occur in the lungs, diaphragm, muscles, heart, and esophagus. Both clinical and histopathological findings are required to confirm the diagnosis of NSF. No cases of NSF have been described in patients with normal kidney function or mild underlying renal disease. The more severe the kidney dysfunction and the higher the dose of gadolinium, the greater is the risk of NSF. NSF develops subacutely in most cases. It usually becomes apparent first in the lower extremities with symmetrical edema that may involve the upper extremities. The edema may be associated with erythema, blisters, and bullae. Upon resolution of the edema, the indurated skin is nonpitting and “unpinchable.” NSF tends to spare the skin of the face, in contrast to both scleroderma and scleromyxedema. Yellow scleral plaques are described in many cases of NSF. The histopathological features of NSF are consistent with a dermal reaction to injury: fibrocyte-like cells, histiocytes, dermal dendritic cells, scar-like fibrosis, mucin, edema, calcification, and ossification. Scleroderma mimickers such as morphea, scleromyxe-dema, and eosinophilic fasciitis are generally distinguished from scleroderma by their absence of extracutaneous disease, Raynaud's phenomenon, and antinuclear antibodies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Broome DR, Girguis MS, Baron PW, et al Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol. 2007;188:586–92
Case Records of MGH. Case 6-2008: A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med. 2008;358:827–38
Centers for Disease Control (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents-St. Louis, Missouri, 2002–2006. Morb Mortal Wkly Rep. 2007; 56(7):137–41
Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): Review of 136 patients. J Am Acad Dermatol. 2008;59(3):385–96
Collidge TA, Thompson PC, Mark PB, et al Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168–75
Cowper SE. Gadolinium: is it to blame? J Cutan Pathol. 2008; 35(5):520–2
Cowper SE, Su L, Robin H, et al Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23(5):383–93
Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect iden-tified, motive unclear [letter]. Am J Dermatopathol. 2003;25(4):35
Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep. 2006a;8(2):151–7
Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: Setting the record straight. Semin Arthritis Rheum. 2006b;35(4):208–10
Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66(2):191–9
Cowper SE. Nephrogenic fibrosing dermopathy [NFD/NSF Website]. 2001–2008. 2007. http://www.icnfdr.org. Accessed 16 Apr 2008
Dawson P, Punwani S. Nephrogenic systemic fibrosis: non-gadolinium options for the imaging of CKD/ESRD patients. Sem Dial. 2008;51:160–5
Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2:264–7
FDA. Information for Healthcare Professionals Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). 2007. http://www.fda.gov/cder/drug/InfoSheets/HCP/gadolinium-con-taining contrast agents_200705.htm
Gonwa TA, Jennings L, Mai ML, et al Estimation of glomerular filtra-tion rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl. 2004;10(2):301–9
Girardi M. Nephrogenic systemic fibrosis: a dermatologist's perspective. J Am Coll Radiol. 2008;5(1):40–4
Grobner T. GBC: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104–8
Grobner T, Prischl FC. Patient characteristics and risk factors for neph-rogenic systemic fibrosis following gadolinium exposure. Sem Dial. 2008;21:135–9
Hawk A, English JC III. Localized and systemic scleroderma. Semin Cutan Med Surg. 2001;20:27–37
High WA, Eng M, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:1–2
Jan F, Segal JM, Dyer J, et al Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr. 2003;143:678–81
Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Sem Dial. 2008;21:123–8
Linfert DR, Schell JO, Fine DM. Treatment of nephrogenic systemic fibro-sis: limited options but hope for the future. Sem Dial. 2008;51:155–9
Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol. 2003;48:55–60
Marckmann P, Skov L, Rossen K, et al Case-control study of gadodi-amide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3174–8
Medicines and Healthcare products Regulatory Agency (MHRA). Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agents: Public Assessment Report. 2007. http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON2030232&RevisionSelectionMethod=LatestReleased Accessed 15 Jul 2008
Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant. 2007;22:3179–85
Perazella MA. Tissue deposition of gadolinium and development of NSF: a convergence of factors. Semin Dial. 2008;21:150–4
Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial. 2007;20:179–85
Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70:1068–76
Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997;24(1):73–80
Sieber MA, Pietsch H, Walter J, et al A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43(1):65–75
Streams BN, Liu V, Liegeois N, Moschella SM. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol. 2003;48:42–7
Swaminathan S, High WA, Ranville J, et al Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 2008; 73(12):1413–18
Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford). 2005;44(3):274–9
Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing der-mopathy with systemic involvement. Arch Dermatol. 2003;139: 903–6
Tuffanelli DL. Localized scleroderma. Semin Cutan Med Surg. 1998; 17:27–33
Weide B, Schittek B, Klyscz T, et al Morphoea is neither associated with features of Borrelia burgdorferi infection, nor is this agent detectable in lesional skin by polymerase chain reaction. Br J Dermatol. 2000;143(4):780–5
Zulian F, Vallongo C, Woo P, et al Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52: 2873–81
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Perazella, M.A., Pope, J.E., Cowper, S.E. (2009). Nephrogenic Systemic Fibrosis and Other Scleroderma Mimickers. In: Stone, J.H. (eds) A Clinician's Pearls and Myths in Rheumatology. Springer, London. https://doi.org/10.1007/978-1-84800-934-9_11
Download citation
DOI: https://doi.org/10.1007/978-1-84800-934-9_11
Publisher Name: Springer, London
Print ISBN: 978-1-84800-933-2
Online ISBN: 978-1-84800-934-9
eBook Packages: MedicineMedicine (R0)